Mesoblast Ltd
MESO10.160USD
-0.275-2.64%
收盘 06/23, 16:00（美东）报价延迟15分钟
1.17B总市值
亏损市盈率 TTM
关于 Mesoblast Ltd 公司
Mesoblast Limited 是一家总部位于澳大利亚的公司，致力于开发用于治疗严重和危及生命的炎症疾病的同种异体（现成）细胞药物。该公司利用其专有的间充质谱系细胞治疗技术平台建立了广泛的后期候选产品组合。该公司正在基于其 remestemcel-L 和 rexlemestrocel-L 同种异体基质细胞技术平台开发用于不同适应症的候选产品。Remestemcel-L 正在开发用于儿童和成人炎症疾病，包括类固醇难治性急性移植物抗宿主病和生物耐药性炎症性肠病。Rexlemestrocel-L 正在开发用于治疗晚期慢性心力衰竭 (REVASCOR) 和慢性腰痛 (MPC-06-ID)。该公司的许可方已在日本和欧洲商业化了两种产品。该公司已在欧洲和中国建立了某些 III 期资产的商业伙伴关系。
公司简介
公司代码MESO
公司名称Mesoblast Ltd
上市日期Dec 16, 2004
成立日期2004
CEODr. Silviu Itescu
员工数量73
证券类型Depository Receipt
年结日Dec 16
公司地址L 38 55 Collins St
城市MELBOURNE
上市交易所NASDAQ Global Select Consolidated
国家Australia
邮编3000
电话61396396036
网址https://www.mesoblast.com/
公司代码MESO
上市日期Dec 16, 2004
成立日期2004
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Eric A. Rose, M.D.
Dr. Eric A. Rose, M.D.
Executive Director, Chief Medical Officer
Executive Director, Chief Medical Officer
41.16K
--
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Philip R. Krause, M.D.
Mr. Philip R. Krause, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Paul Hughes
Mr. Paul Hughes
Joint Company Secretary
Joint Company Secretary
--
--
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
Mr. Philip J. (Phil) Facchina
Mr. Philip J. (Phil) Facchina
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Niva Sivakumar
Ms. Niva Sivakumar
Joint Company Secretary
Joint Company Secretary
--
--
Mr. Paul Hughes
Mr. Paul Hughes
Joint Company Secretary
Joint Company Secretary
--
--
Ms. Niva Sivakumar
Ms. Niva Sivakumar
Joint Company Secretary
Joint Company Secretary
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Eric A. Rose, M.D.
Dr. Eric A. Rose, M.D.
Executive Director, Chief Medical Officer
Executive Director, Chief Medical Officer
41.16K
--
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Philip R. Krause, M.D.
Mr. Philip R. Krause, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Paul Hughes
Mr. Paul Hughes
Joint Company Secretary
Joint Company Secretary
--
--
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
0.44%
Citadel Advisors LLC
0.38%
Morgan Stanley & Co. International Plc
0.25%
Susquehanna International Group, LLP
0.20%
Goldman Sachs & Company, Inc.
0.20%
Other
98.52%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
0.44%
Citadel Advisors LLC
0.38%
Morgan Stanley & Co. International Plc
0.25%
Susquehanna International Group, LLP
0.20%
Goldman Sachs & Company, Inc.
0.20%
Other
98.52%
股东类型
持股股东
占比
Investment Advisor
1.46%
Research Firm
0.99%
Hedge Fund
0.45%
Investment Advisor/Hedge Fund
0.20%
Individual Investor
0.06%
Other
96.83%
机构持股
更新时间: 3月4日 周二
更新时间: 3月4日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q1
121
3.21M
2.52%
-64.68K
2024Q4
122
3.23M
2.55%
+620.09K
2024Q3
100
1.76M
1.52%
-1.23M
2024Q2
98
1.70M
1.52%
-705.91K
2024Q1
97
1.24M
1.12%
-806.95K
2023Q4
94
840.17K
0.85%
-1.02M
2023Q3
97
766.21K
0.94%
-1.35M
2023Q2
99
982.29K
1.21%
-1.15M
2023Q1
103
1.33M
1.81%
-837.80K
2022Q4
108
1.43M
1.94%
-964.96K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
584.29K
0.46%
+584.29K
--
Dec 31, 2024
Morgan Stanley & Co. International Plc
163.50K
0.13%
+163.50K
--
Dec 31, 2024
Susquehanna International Group, LLP
153.98K
0.12%
+37.24K
+31.90%
Dec 31, 2024
Morgan Stanley & Co. LLC
225.25K
0.18%
+54.27K
+31.74%
Dec 31, 2024
Summit Wealth Strategies
145.66K
0.11%
-2.04K
-1.38%
Dec 31, 2024
UBS Financial Services, Inc.
165.15K
0.13%
+165.15K
--
Dec 31, 2024
查看更多
持股ETF
更新时间: 6月6日 周五
更新时间: 6月6日 周五
机构名称
占比
iShares Biotechnology ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
ActivePassive International Equity ETF
0.01%
iShares Biotechnology ETF
占比0.09%
Invesco Nasdaq Biotechnology ETF
占比0.04%
ProShares Ultra Nasdaq Biotechnology
占比0.04%
ActivePassive International Equity ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
公告日期
类型
比率
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
